Drugs / LFD-200
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07207954 | Oct 2025 → Jul 2027 expected | rheumatoid arthritis | Lifordi Immunotherapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LFD-200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07207954 ↗ |
| Route | Subcutaneous | “subcutaneous (SC) doses of LFD-200” NCT07207954 ↗ |